Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer-Reference-Cited by-同舟云学术

Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer

Published:2014-06-18 Issue:2 Volume:74 Page:389-398
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Cao Jun,Zhang Jian,Wang Zhonghua,Wang Biyun,Lv Fangfang,Wang Leiping,Hu Xichun

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-014-2505-x.pdf

Reference50 articles.

1. Banerjee S, Dowsett M, Ashworth A, Martin LA (2007) Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 4(9):536–550

2. Ferrara N (2004) Vascular endothelial growth factor basic science and clinical progress. Endocr Rev 25(4):581–611

3. Seymour L, Dajee D, Bezwoda WR (1993) Tissue platelet derived-growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat 26(3):247–252

4. Hines SJ, Organ C, Kornstein MJ, Krystal GW (1995) Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ 6(6):769–779

5. Miles DW, Chan A, Dirix LY et al (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28(20):3239–3247

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Underlying mechanisms and management strategies for regorafenib-induced toxicity in hepatocellular carcinoma;Expert Opinion on Drug Metabolism & Toxicology;2024-09-03

2. Distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy-sensitive than papillary thyroid cancer;JCI Insight;2024-03-07

3. Effect of Dietary Intake on the Pharmacokinetics of the Multitargeted Receptor Tyrosine Kinase Inhibitor Famitinib: Results From a Phase 1 Study in Healthy Chinese Participants;Clinical Pharmacology in Drug Development;2023-03-03

4. The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects;Cancer Chemotherapy and Pharmacology;2022-09-15

5. Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer;International Journal of Molecular Sciences;2022-08-10